Matthew R. Smith, MD, PhD introduces a nonmetastatic castration-resistant prostate cancer (CRPC) patient case featuring a 52-year-old man referred to urology with a PSA of 6.8 ng/mL.
A 57-Year-Old Man with Nonmetastatic Castration-Resistant Disease
Expert panelist provides his perspective on a CRPC patient case before discussing the typical course of treatment for patients with nonmetastatic CRPC.
Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.
Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
